title: Oral anticoagulant and antiplatelet drugs used in prevention of cardiovascular events in elderly people in Poland.
abstract: BACKGROUND
  In Poland, the prevalence of cardiovascular diseases is increasing. This might be associated with the constantly growing proportion of elderly people and inappropriate cardiovascular prevention. This study aimed to evaluate the frequency of use of oral antiplatelet (OAP) and oral anticoagulant (OAC) drugs among older people in Poland and to assess their association with cardiovascular risk factors.
  
  
  METHODS
  The study was based on data collected during the implementation of a multicentre, publicly funded research project called PolSenior.
  
  
  RESULTS
  The study group consisted of 4,979 people with the average age of 79.35 ± 8.69 years. Among them, 1,787 people (35.9%) used at least one drug in the prevention of cardiovascular diseases. OAPs were used regularly by 1,648 (33.1%) elderly people and OACs were used by 165 elderly people (3.3%). Acetylsalicylic acid was used by 32.2% of elderly people. Use of drugs significantly depended on age (p < 0.01), sex (p < 0.01), place of residence (p < 0.001), level of education (p < 0.0001) and personal income (p < 0.0001). Among all the respondents treated with OAPs, therapy was applied as secondary cardiovascular prevention in 717 respondents (43.5%), and as primary prevention in 705 respondents (42.8%). Among the respondents treated with OACs, 117 (71%) elderly people had a history of atrial fibrillation. Secondary cardiovascular prevention should be considered in a further 482 respondents (15.1% of untreated elderly people), and primary cardiovascular prevention in 1,447 respondents (45.3%).
  
  
  CONCLUSIONS
  Our study is the first to determine the frequency of use of OAP and OAC drugs among elderly people in Poland in relation to cardiovascular risk factors. The most commonly used drug for cardiovascular prevention is acetylsalicylic acid, but it appears that it is used too rarely in high-risk patients. Educational programs should be developed among general practitioners concerning current recommendations for pharmacological cardiovascular prevention.
authors.affiliation: Department of Neurology, Medical University of Silesia, 3-go Maja 13/15, Zabrze 41-800, Poland. beatamaria.pl@hoga.pl
authors.forename: Beata
authors.initials: B
authors.lastname: Labuz-Roszak
authors.forename: Krystyna
authors.initials: K
authors.lastname: Pierzchala
authors.forename: Michal
authors.initials: M
authors.lastname: Skrzypek
authors.forename: Marta
authors.initials: M
authors.lastname: Swiech
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Machowska-Majchrzak
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011044:Poland; D012307:Risk Factors
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors